Minsheng Royal CSI Biotechnology Theme ETF

Morgan Stanley Predicts China's Biotech Sector to Fluctuate in H1 and See Clearer Direction in H2

Shenzhen Releases Action Plan for Insurance Industry to Support Innovation

159837

516500

159849

SBIO

513290

159859

512290

516930

588250

159615

159102

Athena FH sold 5.6 million shares in Carel, approximately 5% of the share capital, at EUR 30.1 per share. Post-sale, Athena FH will hold 13.81% of the share capital and 18.68% of voting rights. Settlement is set for May 25, 2026.

PUBT

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

SPDR S&P Biotech

China Merchants CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

Ping An CSI Medicine and Medical Device Innovation ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Proshares UltraShort Nasdaq Biotech

Proshares Ultra Nasdaq Biotech

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Invesco Nasdaq Biotechnology ETF

Penghua SSE STAR Biology and Medicine ETF

iShares Genomics Immunology and Healthcare ETF

VanEck Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Huaan Hang Seng Biotech ETF

iShares Biotechnology ETF

Athena FH holds 13.81% stake, 18.68% voting rights in Carel after sale

688235

159992

512010

510660

BeOne Medicines' BCL-2 inhibitor Sotorasib has received accelerated approval from the FDA, becoming the first new BCL-2 targeted drug approved in the United States in the past decade, suitable for relapsed/refractory mantle cell lymphoma. The company expects net profit in the first quarter to exceed 1.6 billion yuan, with revenue expectations raised to between 43.6 billion and 45.2 billion yuan, maintaining a gross margin of 80%. This move is expected to break the reliance on a single product and enhance medication adherence among patients and doctors

BambooWorks

BeOne Medicines

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal 800 Health Care ETF

BEONE MEDICINES

Beigene

Hang Seng Index

Amgen

BeOne Medicines is expected to break the "single product dependence" with a net profit exceeding 1.6 billion yuan in the first quarter

Ipsen announced results from the Phase IV DIRECTION trial, the first head-to-head study comparing Dysport and Botox for upper limb spasticity. Dysport showed non-inferiority in safety and a longer duration of effect (14.2 weeks vs. 13.8 weeks). The trial involved 464 adults across 72 sites and addressed a significant need for longer-lasting treatment. The findings were presented at the ISPRM World Congress in Vancouver. Ipsen's stock is currently trading at EUR 158.10, up 0.32%.

nasdaq

Health Care Select Sector SPDR

iShares US Pharma

VG Health

Nasdaq

Ipsen Reports First Head-to-Head Data Showing Dysport Provides Longer Symptom Control Than Botox

01011

513700

China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices.

Tip Ranks

NT PHARMA

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

The Purina Institute is advancing microbiome science in veterinary medicine, focusing on the gut-brain axis and antimicrobial stewardship. Their Microbiome Forum highlighted how gut health influences neurological conditions in pets and emphasized the need for responsible antimicrobial use to protect long-term health. By translating complex research into practical insights, the Institute aims to empower veterinarians to enhance pet health through informed dietary and treatment strategies.

prnewswire

08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine

Annovis Bio, Inc. announced a proposed underwritten public offering of common stock and accompanying warrants. The offering aims to raise funds for the clinical development of its lead compound, buntanetap, for Alzheimer's and Parkinson's diseases. Canaccord Genuity is the sole bookrunner. The offering is subject to market conditions and is detailed in a preliminary prospectus to be filed with the SEC.

StockTitan

Annovis Bio

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants | ANVS Stock News

Nanjing's Leads Biolabs Co., Ltd. revealed today that their exclusive PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has been approved by the Center for Drug Evaluation. This announcement was made under the Stock Code.

Unusual Whales

LEADS BIOLABS-B

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. announced that its PD-L1/4-1BB bispecific antibody, Opamtistomig, has received approval for a pivotal Phase III trial for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). This marks a shift from late-line to first-line treatment, expanding its patient population. The study, led by Professor Lin Shen, aims to validate Opamtistomig's potential to improve patient survival. The company plans to submit a Biologics License Application in Q3 2026 and is advancing multiple trials across various solid tumor indications.

21:35 ETLeads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

01801

159316

159570

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

Minsheng Royal CSI Biotechnology Theme ETF(516930.SH)